BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens BIO REBOOT Registration, Announces PDAOAI Presentations at Drug Discovery 2026 

Oncotelic Therapeutics (OTCQB: OTLC), together with its wholly owned subsidiary Pet2DAO, Inc., announced that its PDAOAI artificial intelligence-powered drug discovery platform is inviting scientists, AI developers and biotech founders to participate in BIO REBOOT. Participants can bring research questions, technical expertise and drug discovery ideas to the PDAOAI community, with selected projects potentially considered for startup funding and Oncotelic support covering validation, formulation, regulatory planning and clinical development.

Oncotelic also announced two PDAOAI keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, taking place Oct. 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will present a hepatocellular carcinoma case study illustrating how Partitioned Literature Aggregation generated a candidate four-gene signature, while Product Manager Scott Myers will discuss AI search aggregation for biomedical knowledge discovery in drug development.

To view the full press release, visit https://ibn.fm/Es0iR

About Oncotelic

Oncotelic Therapeutics, Inc. develops oncology and immunotherapy products, with a focus on cancers with substantial unmet needs and rare pediatric indications. The Company also develops the PDAOAI platform to support its work in drug discovery and development.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Attention as ‘Men’s Fitness’ Highlights unbuzzd Trial Results

Quantum BioPharma (NASDAQ: QNTM) is gaining broader consumer exposure following a recent Men’s Fitness review…

2 days ago

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Advances Peptide Innovation and GLP-1 Companion Strategy

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…

4 days ago

BioMedNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Schedules Third Quarter 2026 Financial Results and Conference Call for Nov. 25

Nanox (NASDAQ: NNOX) announced plans to showcase its medical imaging technologies at the Radiological Society…

4 days ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 Operational Highlights and Advances AI-Driven Oncology Pipeline

Lantern Pharma (NASDAQ: LTRN) reported operational highlights and financial results for the third quarter ended…

4 days ago

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Receives USPTO Notice of Allowance for Abuse-Deterrent Fentanyl Patch Brand Names

Nutriband (NASDAQ: NTRB) announced that it received a Notice of Allowance dated Nov. 3, 2026,…

5 days ago